Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.43 |
| ▸ | PAK4 | O96013 | 2/20 | 0.43 |
| ▸ | NMT1 | P30419 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | CLK1 | P49759 | 3/20 | 0.36 |
| ▸ | CLK2 | P49760 | 3/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.36 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.36 |
| ▸ | CLK3 | P49761 | 1/20 | 0.36 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12185784 | 1.00 | PAK1 (0.43) | PAK1PAK4NMT1ABL1SRC | |
| SCHEMBL3392875 | 0.91 | NMT1 (0.44) | PAK1PAK4NMT1ABL1SRC | |
| SCHEMBL12185491 | 0.89 | EGFR (0.47) | PAK1PAK4ABL1SRCHDAC1 | |
| SCHEMBL12185447 | 0.86 | PAK1 (0.44) | PAK1PAK4NMT1ABL1SRC | |
| SCHEMBL12185464 | 0.86 | PAK1 (0.44) | PAK1PAK4NMT1ABL1SRC | |
| SCHEMBL16494864 | 0.84 | MAPT (0.43) | LMNATDP1 | |
| SCHEMBL16494682 | 0.84 | MAPT (0.43) | LMNATDP1 | |
| SCHEMBL12185305 | 0.82 | CLK1 (0.55) | PAK1PAK4NMT1CLK1CLK2 | |
| SCHEMBL12185465 | 0.81 | EPHB4 (0.46) | PAK1PAK4EGFRCLK4 | |
| SCHEMBL12185449 | 0.81 | EGFR (0.54) | NMT1ABL1SRCHDAC1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2571867-B1 | NOVEL PYRIMIDINE DERIVATIVES | NOVIGA RES AB (SE) | 2015-11-04 | — | — | EP | disclosed |
| US-8927547-B2 | Pyrimidine derivatives | NOVIGA RESEARCH AB (SE) | 2015-01-06 | — | — | US | disclosed |
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2013-04-11 | — | — | US | disclosed |
| WO-2011144742-A1 | NOVEL PYRIMIDINE DERIVATIVES | CHEMILIA AB (SE) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089518-A1 | NOVEL PYRIMIDINE DERIVATIVES | DPYD, TYMS, TYMP | PAK1 2538/4885PAK4 2611/4885NMT1 2524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.